Oncternal Therapeutics, Inc. announced that Damien Bresson as Senior Director, Preclinical and Translation Science.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.4 USD | +1.33% | -1.75% | -21.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.67% | 24.54M | |
+2.12% | 42.75B | |
+47.64% | 41.61B | |
+12.27% | 41.34B | |
-12.36% | 26.59B | |
+8.29% | 25.49B | |
-23.23% | 18.12B | |
+30.25% | 12.24B | |
-1.37% | 11.76B | |
+8.47% | 11B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science